Pila Pharma Begins Obesity Trial Enrollment
Pila Pharma has activated the site for PP-CT04, its 12-week trial of oral TRPV1 antagonist XEN-D0501 in obesity. The company began enrolling the initial safety cohort of eight participants, with six screened on day one.